Treatment of premenstrual dysphoria with selective serotonin re-uptake inhibitors: Focus on safety

Expert Opinion on Drug Safety

Volumn 2, Issue 2, 2003, Pages 161-166

  MacDougall, Mary ^a   Steiner, Meir ^a  

^a Women's Health Concerns Clinic   (Canada)

Author keywords

premenstrual dysphoric disorder (PMDD); premenstrual syndrome (PMS); selective serotonin re uptake inhibitors (SSRIs)

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

BREAST FEEDING; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG INTERACTION; FEMALE; HUMAN; PATIENT COMPLIANCE; PREGNANCY; PREMENSTRUAL SYNDROME; PSYCHOLOGICAL ASPECT; REVIEW; RISK ASSESSMENT;

BREAST FEEDING; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; PATIENT COMPLIANCE; PREGNANCY; PREMENSTRUAL SYNDROME; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS;

EID: 0042495751     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2.2.161     Document Type: Review

References (71)

1. JOHNSON SR, MCCHESNEY C, BEAN JA: Epidemiology of premenstrual symptoms in a nonclinical sample. I. Prevalence, natural history and help-seeking behavior. J. Reprod. Med. (1988) 33:340-346.
2. RAMCHARAN S, LOVE EJ, FICK GH et al.: The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors. J. Clin. Epidemiol. (1992) 45:377-392.
3. WORLD HEALTH ORGANIZATION: Mental, behavioural and developmental disorders. In: 10th Revision of the International Classification of Diseases (ICD-10). Geneva (1996).
4. STEINER M, YONKERS KA: Depression in Women. Martin Dunitz Ltd, London, UK (1998).
5. JOHNSON WG, CARR-NANGLE RE, BERGERON KC: Macronutrient intake, eating habits, and exercise as moderators of menstrual distress in healthy women. Psychosom. Med. (1995) 57:324-330.
6. LAM RW, CARTER D, MISRI S, KUAN AJ, YATHAM LN, ZIS AP: A controlled study of light therapy in women with late luteal phase dysphoric disorder. Psychiatry Res. (1999) 86:185-192.
7. BLAKE F, SALKOVSKIS P, GATH D, DAY A, GARROD A: Cognitive therapy for premenstrual syndrome: a controlled trial. J. Psychosom. Res. (1998) 45:307-318.
8. THYS-JACOBS S, STARKEY P, BERNSTEIN D, TIAN J: Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Am. J. Obstet. Gynecol. (1998) 179:444-452.
9. WALKER AF, DESOUZE MC, VICKERS MF, ABEYASEKERA S, COLLINS ML, TRINCA LA: Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J. Womens Health. (1998) 7:1157-1165.
10. FACCHINETTI F, BORELLA P, SANCES G, FIORONI L, NAPPI RE, GENAZZANI AR: Oral magnesium successfully relieves premenstrual mood changes. Obstet. Gynecol. (1991) 78:177-181.
11. WYATT KM, DIMMOCK PW, JONES PW et al.: Efficacy of vitamin B6 in the treatment of premenstrual syndrome: systematic review. Br. Med. J. (1999) 318:1375-1381.
12. MIRA M, MCNEIL D, FRASER IS, VIZZARD J, ABRAHAM S: Mefenamic acid in the treatment of premenstrual syndrome. Obstet. Gynecol. (1986) 68:395-398.
13. SANCES G, MARTIGNONI E, FIORONI L, BLANDINI F, FACCHINETTI F, NAPPI G: Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache (1990) 30:705-709.
14. ANDERSCH B: Bromocriptine and premenstrual symptoms: a survey of double blind trials. Obstet. Gynecol. Surv. (1983) 38:643-646.
15. O'BRIEN PMS, CRAVEN D, SELBY C, SYMONDS EN: Treatment of premenstrual syndrome by spironolactone. Br. J. Obstet. Gynaecol. (1979) 86:142-147.
16. VELLACOTT ID, SHROFF NE, PEARCE MY et al.: A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome. Curr. Med. Res. Opin. (1987) 10:450-460.
17. WANG M, HAMMARBACK S, LINDHE B-A, BACKSTROM T: Treatment of premenstrual syndrome by spironolactone: a double-blind, placebocontrolled study. Acta Obstet. Gynecol. Scand. (1995) 74:803-808.
18. WITTCHEN H-U, BECKER E, LIEB R, KRAUSE P: Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psycholog. Med. (2002) 32:119-132.
19. STERNFELD B, SWINDLE R, CHAWLA A, LONG S, KENNEDY S: Severity of premenstrual symptoms in a health maintenance organization population. Obstet. Gynecol. (2002) 6:1014-1024.
20. GEHLERT S, HARTLAGE S: A design for studying the DSM-IV research criteria of premenstrual dysphoric disorder. J. Psychosom. Obstet. Gynecol. (1997)18:36-44.
21. ANDERSCH B, WENDESTAM C, HAHN L, OHMAN R: Premenstrual complaints. Prevalence of premenstrual symptoms in a Swedish urban population. J. Psychosom. Obstet. Gynecol. (1986) 5:39-49.
22. JOHNSON SR: The epidemiology and social impact of premenstrual symptoms. Clin. Obstet. Gynecol. (1987) 30:367-376.
23. PEARLSTEIN TB, HALBREICH U, BATZAR ED et al.: Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J. Clin. Psychiatry (2000) 61:101-109.
24. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and statistical manual of mental disorders, (3rd edn). Revised. Washington, DC, USA (1987).
25. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and statistical manual of mental disorders, (4th edn). Washington, DC, USA (1994).
26. DIMMOCK PW, WYATT KM, JONES PW, O'BRIEN PMS: Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet (2000) 356:1131-1136.
27. WIKANDER I, SUNDBLAD C, ANDERSCH B et al.: Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J. Clin. Psychopharmacol. (1998) 18:390-398.
28. STEINER M, KORZEKWA M, LAMONT J, WILKINS A: Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol. Bull. (1997) 33:771-774.
29. JERMAIN ET, PREECE CK, SYKES RL, KUEHL TJ, SULAK PJ: Luteal phase sertraline treatment for premenstrual dysphoric disorder. Arch. Fam. Med. (1999) 8:328-332.
30. STEINER M, STEINBERG S, STEWART D et al.: Fluoxetine in the treatment of premenstrual dysphoria. N. Engl. J. Med. (1995) 332:1529-1534.
31. STEINER M, BORN L: Advances in the diagnosis and treatment of premenstrual dysphoria. CNS Drugs (2000) 13(4):287-304.
32. STEINER M, PEARLSTEIN T: Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J. Clin. Psychiatry (2000) 61(Suppl. 12):17-21.
33. HALBREICH U, BERGERON R, YONKERS KA, FREEMAN E, STOUTAL, COHEN L: Efficacy of intermittent, luteal phase, sertraline treatment of premenstrual dysphoric disorder. Am. J. Obstet. Gynecol. (2002) 100:1219-1229.
34. FREEMAN EW, RICKELS K, ARRENDANDO F, KAO L-C, POLLACK SE, SONDHEIMER SJ: Full or half cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J. Clin. Psychopharmacol. (1999) 19:3-8.
35. MINER C, BROWN E, MCCRAY S, GONZALES J, WOHLREICH M: Weekly luteal-phase dosing with entericcoated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, doubleblind, placebo-controlled clinical trial. Clin. Ther. (2002) 24(3):417-433.
36. COHEN LS, MINER CM, BROWN EB et al.: Premenstrual daily fluoxetine for PMDD: a placebo-controlled clinical trial using computerized diaries. Obstet. Gynecol. (2002) 100:435-444.
37. YONKERS K, HALBREICH U, FREEMAN EW et al.: Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: a randomized controlled trial. JAMA (1997) 278:983-988.
38. ERIKSSON E, HEDBERG MA, ANDERSCH B, SUNDBLAD C: The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual dysphoria. Neuropsychopharmacology (1995) 12:167-176.
39. MASAND PS, GUPTA S: Selective serotonin-reuptake inhibitors: an update. Harvard Rev. Psychiatry (1999) 7(2):69-84.
40. ENDICOTT J, AMSTERDAM J, ERIKSSON et al.: Is premenstrual dysphoric disorder a distinct clinical entity? J. Womens Health Gend. Med. (1999) 8(5):663-679.
41. MONTELEONE P, LUISI S, TONETTI A et al.: Allopregnanolone concentrations and premenstrual syndrome. Eur. J. Endocrinol. (2000) 142:269-273.
42. RAPKIN AJ, MORGAN M, GOLDMAN L, BRANN DW, SIMONE D, MAHESH VB: Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet. Gynecol. (1997) 90:709-714.
43. SCHMIDT PJ, NIEMAN LK, DANACEAU MA, ADAMS LF, RUBINOW DR: Differential behavioral effects of gonadal steroid in women with and in those without premenstrual syndrome. N. Engl. J. Med (1998) 338(4):209-216.
44. PEARLSTEIN TB, STONE AB, LUND SA, SCHEFT H, ZLOTNICK C, BROWN WA: Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J. Clin. Psychopharmacol. (1997) 17:261-266.
45. FREEMAN EW, RICKELS K, SONDHEIMER SJ, WITTMAACK FM: Sertraline versus desipramine in the treatment of premenstrual syndrome: an open-label trial. J. Clin. Psychiatry (1996) 57:7-11.
46. SUNDBLAD C, MODIGH K, ANDERSCH B, ERIKSSON E: Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr. Scand. (1992) 85:39-47.
47. SUNDBLAD C, HEDBERG MA, ERIKSSON E: Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology (1993) 9:133-145.
48. ERIKSSON E, ANDERSCH B, HO HP, LANDEN M, SUNDBLAD C: Diagnosis and treatment of premenstrual dysphoria. J. Clin. Psychiatry (2002) 63(Suppl. 7):16-23.
49. STEINER M: Premenstrual syndrome and premenstrual dysphoric disorder: guidelines for management. J. Psychiatry Neurosci. (2000) 25:459-468.
50. ROSEN RC, LANE RM, MENZA M: Effects of SSRIs on sexual function: a critical review. J. Clin. Psychopharmacol. (1999) 19:67-85.
51. PEARLSTEIN TB, STONE AB: Long-term fluoxetine treatment of late luteal phase dysphoric disorder. J. Clin. Psychiatry (1994) 58(5):332-335
52. ROTHSCHILD AJ: Sexual side effects of antidepressants. J. Clin. Psychiatry (2000) 61(Suppl. 11):28-36.
53. ZAJECKA J, TRACY KA, MITCHELL S: Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J. Clin. Psychiatry (1997) 58(Suppl. 7):291-296.
54. KOKE SC, BROWN EB, MINER CM: Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy. Am. J. Obstet. Gynecol. (2002) 187:551-555.
55. STEINER M, LAMONT J, STEINBERG S, STEWART D, REID R, STREINER D: Effect of fluoxetine on menstrual cycle length in women with premenstrual dysphoria. Obstet. Gynecol. (1997) 90:1-5.
56. PASTUSZAK A, SCHICKBOSCHETTO B, ZUBER C et al.: Pregnancy outcome following first trimester exposure to fluoxetine. JAMA (1993) 269:2246-2248.
57. GOLDSTEIN DJ, CORBIN LA, SUNDELL KL: Effect of first-trimester fluoxetine exposure on the newborn. Obstet. Gynecol. (1997) 89(5 Pt 1):713-718.
58. COHEN LS, ROSENBAUM JF: Psychotropic drug use during pregnancy: weighing the risks. J. Clin. Psychiatry (1998) 59(Suppl. 2):18-28.
59. GOLDSTEIN DJ, SUNDELL KL, CORBIN LA: Birth outcomes in pregnant women taking fluoxetine. Letter to Editor. N. Engl. J. Med. (1997) 336(12):872-873.
60. NULMAN I, ROVET J, STEWART DE et al.: Neurodevelopment of children exposed in utero to antidepressant drugs. N. Engl. J. Med. (1997) 336:258-262.
61. KULIN NA, PASTUSZAK A, SAGE SR et al.: Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. JAMA (1998) 279:609-610.
62. DILER RS, RAMAM L, AVCI A: Paroxetine use during breast-feeding. J. Clin. Psychopharmacol. (2000) 20:587-589.
63. SURI R, STOWE ZN, HENDRICK V, HOSTETTER A, WIDAWSKI M, ALTSHULER LL: Estimates of nursing infant daily dose of fluoxetine through breast milk. Biol. Psychiatry (2002) 52:446-451.
64. STOWE ZN, COHEN LS, HOSTETTER A, RITCHIE JC, OWENS MJ, NEMEROFF CB: Paroxetine in human breast milk and nursing infants. Am. J. Psychiatry (2000)157:185-189.
65. HENDRICK V, STOWE ZN, ALTSHUYLER LL et al.: Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. Biol. Psychiatry (2001) 50:775-782.
66. PIONTEK CM, WISNER KL, PEREL JM, PEINDL KS: Serum fluvoxamine levels in breastfed infants. J. Clin. Psychiatry (2001) 62:111-113.
67. SCHMIDT K, OLSON OV, JENSEN PN: Citalopram and breast-feeding: serum concentration and side effects in the infant. Biol. Psychiatry (2000) 47:164-165.
68. WISNER KL, PEREL JM, BLUMER J: Serum sertraline and N-desmethylsertraline levels in breast-feeding mother-infant pairs. Am. J. Psychiatry (1998) 155:690-692.
69. HOFFBRAND S, HOWARD L, CRAWLEY H: Antidepressant drug treatment for postnatal depression (Cochrane Review). In: The Cochrane Library, Issue 2. Update Software, Oxford (2001).
70. NEWPORT DJ, HOSTETTER A, ARNOLD A, STOWE ZN: The treatment of postpartum depression: minimizing infant exposures. J. Clin. Psychiatry (2002) 63(Suppl. 7):31-44.
71. HYLAN TR, SUNDELL K, JUDGE R: The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom and France. J. Womens Health Gend. Based Med. (1999) 8:1043-1052.